ORGANOGENESIS HOLDINGS INC. Depreciation
ORGANOGENESIS HOLDINGS INC. (ORGO) reported Depreciation of $15.27 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Cash Flow › Operating Activities
us-gaap:Depreciation · last filed 2026-02-26
- ORGANOGENESIS HOLDINGS INC. depreciation for the quarter ending 2025-12-31 was $4.07M, a 12.48% increase year-over-year.
- ORGANOGENESIS HOLDINGS INC. depreciation for the quarter ending 2025-09-30 was $4.03M, a 12.86% increase year-over-year.
- ORGANOGENESIS HOLDINGS INC. depreciation for the quarter ending 2025-06-30 was $3.73M, a 10.93% increase year-over-year.
- ORGANOGENESIS HOLDINGS INC. depreciation for the quarter ending 2025-03-31 was $3.44M, a 12.11% increase year-over-year.
- ORGANOGENESIS HOLDINGS INC. depreciation for fiscal 2025 was $15.27M, a 12.11% increase from fiscal 2024.
- ORGANOGENESIS HOLDINGS INC. depreciation for fiscal 2024 was $13.62M, a 30.39% increase from fiscal 2023.
- ORGANOGENESIS HOLDINGS INC. depreciation for fiscal 2023 was $10.45M, a 78.75% increase from fiscal 2022.
- ORGANOGENESIS HOLDINGS INC. depreciation for fiscal 2022 was $5.84M, a 1.11% increase from fiscal 2021.
| Period end | Depreciation 3 month | Depreciation 3 month as first filed | Depreciation 6 month | Depreciation 9 month | Depreciation 9 month as first filed | Depreciation 12 month | Depreciation 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2025-12-31 | $4.07M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $8.10M derived: sum of 2 quarters · filed 2026-02-26 | $11.83M derived: sum of 3 quarters · filed 2026-02-26 | $15.27M 10-K · filed 2026-02-26 | |||
| 2025-09-30 | $4.03M 10-Q · filed 2025-11-06 | $7.76M derived: sum of 2 quarters · filed 2025-11-06 | $11.21M 10-Q · filed 2025-11-06 | $14.82M derived: sum of 4 quarters · filed 2026-02-26 | |||
| 2025-06-30 | $3.73M 10-Q · filed 2025-08-07 | $7.18M 10-Q · filed 2025-08-07 | $10.79M derived: sum of 3 quarters · filed 2026-02-26 | $14.36M derived: sum of 4 quarters · filed 2026-02-26 | |||
| 2025-03-31 | $3.44M 10-Q · filed 2025-05-08 | $7.06M derived: sum of 2 quarters · filed 2026-02-26 | $10.63M derived: sum of 3 quarters · filed 2026-02-26 | $13.99M derived: sum of 4 quarters · filed 2026-02-26 | |||
| 2024-12-31 | $3.62M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $7.18M derived: sum of 2 quarters · filed 2026-02-26 | $10.55M derived: sum of 3 quarters · filed 2026-02-26 | $13.62M 10-K · filed 2026-02-26 | |||
| 2024-09-30 | $3.57M 10-Q · filed 2025-11-06 | $6.94M derived: sum of 2 quarters · filed 2025-11-06 | $10.01M 10-Q · filed 2025-11-06 | $12.99M derived: sum of 4 quarters · filed 2026-02-26 | |||
| 2024-06-30 | $3.37M 10-Q · filed 2025-08-07 | $6.44M 10-Q · filed 2025-08-07 | $9.42M derived: sum of 3 quarters · filed 2026-02-26 | $11.96M derived: sum of 4 quarters · filed 2026-02-26 | |||
| 2024-03-31 | $3.07M 10-Q · filed 2025-05-08 | $6.05M derived: sum of 2 quarters · filed 2026-02-26 | $8.60M derived: sum of 3 quarters · filed 2026-02-26 | $10.83M derived: sum of 4 quarters · filed 2026-02-26 | |||
| 2023-12-31 | $2.98M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $5.53M derived: sum of 2 quarters · filed 2026-02-26 | $7.75M derived: sum of 3 quarters · filed 2026-02-26 | $10.45M 10-K · filed 2026-02-26 | |||
| 2023-09-30 | $2.54M 10-Q · filed 2023-11-09 | $4.77M derived: sum of 2 quarters · filed 2023-11-09 | $7.47M 10-Q · filed 2023-11-09 | $8.98M derived: sum of 4 quarters · filed 2025-02-27 | |||
| 2023-06-30 | $2.23M 10-Q · filed 2023-08-09 | $4.92M 10-Q · filed 2023-08-09 | $6.44M derived: sum of 3 quarters · filed 2025-02-27 | $7.89M derived: sum of 4 quarters · filed 2025-02-27 | |||
| 2023-03-31 | $2.69M 10-Q · filed 2024-05-09 | $4.21M derived: sum of 2 quarters · filed 2025-02-27 | $5.66M derived: sum of 3 quarters · filed 2025-02-27 | $7.19M derived: sum of 4 quarters · filed 2025-02-27 | |||
| 2022-12-31 | $1.51M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $2.97M derived: sum of 2 quarters · filed 2025-02-27 | $4.50M derived: sum of 3 quarters · filed 2025-02-27 | $5.84M 10-K · filed 2025-02-27 | |||
| 2022-09-30 | $1.46M 10-Q · filed 2023-11-09 | $2.98M derived: sum of 2 quarters · filed 2023-11-09 | $4.33M 10-Q · filed 2023-11-09 | $6.10M derived: sum of 4 quarters · filed 2024-02-29 | |||
| 2022-06-30 | $1.53M 10-Q · filed 2023-08-09 | $2.88M 10-Q · filed 2023-08-09 | $4.65M derived: sum of 3 quarters · filed 2024-02-29 | $6.58M derived: sum of 4 quarters · filed 2024-02-29 | |||
| 2022-03-31 | $1.35M 10-Q · filed 2023-05-10 | $3.12M derived: sum of 2 quarters · filed 2024-02-29 | $5.05M derived: sum of 3 quarters · filed 2024-02-29 | $6.12M derived: sum of 4 quarters · filed 2024-02-29 | |||
| 2021-12-31 | $1.77M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $3.71M derived: sum of 2 quarters · filed 2024-02-29 | $4.77M derived: sum of 3 quarters · filed 2024-02-29 | $5.78M 10-K · filed 2024-02-29 | |||
| 2021-09-30 | $1.94M 10-Q · filed 2022-11-09 | $3.00M derived: sum of 2 quarters · filed 2022-11-09 | $4.01M 10-Q · filed 2022-11-09 | $5.16M derived: sum of 4 quarters · filed 2023-03-01 | |||
| 2021-06-30 | $1.06M 10-Q · filed 2022-08-09 | $2.07M 10-Q · filed 2022-08-09 | $3.23M derived: sum of 3 quarters · filed 2023-03-01 | $4.36M derived: sum of 4 quarters · filed 2023-03-01 | |||
| 2021-03-31 | $1.01M 10-Q · filed 2022-05-10 | $2.16M derived: sum of 2 quarters · filed 2023-03-01 | $3.30M derived: sum of 3 quarters · filed 2023-03-01 | $4.19M derived: sum of 4 quarters · filed 2023-03-01 | |||
| 2020-12-31 | $1.15M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $2.29M derived: sum of 2 quarters · filed 2023-03-01 | $3.18M derived: sum of 3 quarters · filed 2023-03-01 | $4.44M 10-K · filed 2023-03-01 | $3.72M 10-K · filed 2021-03-16 | ||
| 2020-09-30 | $1.14M 10-Q · filed 2021-11-09 | $956.00K 10-Q · filed 2020-11-09 | $2.03M derived: sum of 2 quarters · filed 2021-11-09 | $3.29M 10-Q · filed 2021-11-09 | $2.75M 10-Q · filed 2020-11-09 | $4.16M derived: sum of 4 quarters · filed 2022-03-01 | |
| 2020-06-30 | $891.00K 10-Q · filed 2021-08-09 | $1.79M 10-Q · filed 2021-08-09 | $3.02M derived: sum of 3 quarters · filed 2022-03-01 | $3.81M derived: sum of 4 quarters · filed 2022-03-01 | |||
| 2020-03-31 | $902.00K 10-Q · filed 2021-05-11 | $2.13M derived: sum of 2 quarters · filed 2022-03-01 | $2.92M derived: sum of 3 quarters · filed 2022-03-01 | $3.78M derived: sum of 4 quarters · filed 2022-03-01 | |||
| 2019-12-31 | $1.23M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $2.02M derived: sum of 2 quarters · filed 2022-03-01 | $2.88M derived: sum of 3 quarters · filed 2022-03-01 | $3.78M 10-K · filed 2022-03-01 | $3.39M 10-K · filed 2020-03-09 | ||
| 2019-09-30 | $792.00K 10-Q · filed 2020-11-09 | $1.65M derived: sum of 2 quarters · filed 2020-11-09 | $2.55M 10-Q · filed 2020-11-09 | $3.25M derived: sum of 4 quarters · filed 2021-03-16 | |||
| 2019-06-30 | $859.00K 10-Q · filed 2020-08-10 | $1.76M 10-Q · filed 2020-08-10 | $2.46M derived: sum of 3 quarters · filed 2021-03-16 | $3.32M derived: sum of 4 quarters · filed 2021-03-16 | |||
| 2019-03-31 | $902.00K 10-Q · filed 2020-05-11 | $1.60M derived: sum of 2 quarters · filed 2021-03-16 | $2.46M derived: sum of 3 quarters · filed 2021-03-16 | $3.34M derived: sum of 4 quarters · filed 2021-03-16 | |||
| 2018-12-31 | $701.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-16 | $1.56M derived: sum of 2 quarters · filed 2021-03-16 | $2.44M derived: sum of 3 quarters · filed 2021-03-16 | $3.31M 10-K · filed 2021-03-16 | |||
| 2018-09-30 | $861.00K 10-Q · filed 2019-11-12 | $1.74M derived: sum of 2 quarters · filed 2019-11-12 | $2.61M 10-Q · filed 2019-11-12 | ||||
| 2018-06-30 | $875.00K 10-Q · filed 2019-08-09 | $1.75M 10-Q · filed 2019-08-09 | |||||
| 2018-03-31 | $872.00K 10-Q · filed 2019-05-10 | ||||||
| 2017-12-31 | $3.59M 10-K · filed 2020-03-09 | ||||||
| 2016-12-31 | $5.70M 10-K · filed 2019-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |